Figure 7.(A) NCAPD2 expression was higher in responders than in nonresponders in urothelial carcinoma patients treated with PD-L1 inhibitor atezolizumab. (B) The Kaplan-Meier survival of NCAPD2 in low- and high-expression treated with PD-1 in melanoma.
